Site last updated:
July 2010
Cancer Services Forum currently has 713 registered members
Conference Reports
These consist of reports on key commissioning conferences, meetings or symposia.
The Editorial Advisory Board invites readers to send in reports from any relevant meetings for publication.
Recent Conference Reports include
New cancer medicines: Joint working between the NHS and the pharmaceutical industry
0 comment on this article -
Be the first to comment
Closer working between the NHS and the pharmaceutical industry has been a key theme in cancer commissioning this year.
It also proved to be an important topic at the first national conference of the North of England Cancer Drugs Approval Group (NECDAG), where speakers from both camps discussed how they could work together to improve access to medicines for cancer patients. We bring readers a full report by Conference Chair, Steve Williamson.
Cancer Commissioning—at a global and a local level: London Cancer New Drugs Group Annual Meeting
0 comment on this article -
Be the first to comment
Another year, another outstanding London Cancer New drugs Group (LCNDG) annual meeting—and, as ever, a brilliant gathering of committed delegates to keep the presenters on their toes.
Patient-access schemes (PASs) dominated the proceedings, with lively discussions on, for example, risk-share, top-up payments and the emerging role of the PAS Liaison Unit (PASLU) part of the National Institute for Health and Clinical Excellence (NICE).
Read on for a full report on the talks from: Professor Adrian Newland, David Webb, Andy Stainthorpe, Dr Paul Catchpole, Helen Knight, Professor Christopher McCabe, Rod Griffiths, Nick Bosanquet, Dr Monica Desai and Dr Andy Mitchell plus lively discussion from the meeting.
Commissioning Cancer Drugs and Services. The London Cancer New Drugs Group Meeting
0 comment on this article -
Be the first to comment
The London Cancer New Drugs Group (LCNDG) conference was perfectly timed. Professor Mike Richards had just issued his recommendation that NHS patients should be allowed to pay for additional medicines, and the conference coincided with the week that saw reports on cancer therapy published by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the National Chemotherapy Advisory Group Report (NCAG).
The agenda for the 2008 London Cancer New Drugs Group (LCNDG) meeting asked three key questions. How will chemotherapy fit into the broader “world class” NHS commissioning imperative? How is the role of health technology assessment (HTA) groups evolving? What are the factors that influence their decisions?
The London Cancer New Drugs Group Meeting 2008
0 comment on this article -
Be the first to comment
The first London Cancer New Drugs Group (LCNDG) conference held in March 2007 was a great success, particularly because it prompted a debate about how all partners in health care needed to work together to ensure a timely and equitable introduction of new cancer drugs. The second conference, in January 2008, was timed to allow discussion on the recently published Cancer Reform Strategy.
Commissioning Cancer Drugs and Services
0 comment on this article -
Be the first to comment
To say that the imposing façade of RIBA headquarters instilled in arriving delegates a sense of trepidation would be pure conjecture; that the conference to which they were arriving would ask more questions than it answered, however, must have been forecast by all 200 who attended.
Convened by the London Cancer New Drugs Group (LCNDG) to discuss the commissioning of cancer drugs and services, the aims of the conference were three-fold:
- To explore how cancer drugs and supportive care could be effectively commissioned alongside cancer services and within the context of the wider commissioning agenda
- To discuss environmental changes that might alter the role of health technology assessment
- To facilitate an understanding of the work of the LCNDG and other health technology appraisal (HTA) bodies amongst stakeholders, including commissioners and the pharmaceutical industry
Page 1 of 1 pages
